Dabogratinib for low grade upper tract urothelial carcinoma
Part of Cancer, Kidney & urinary clinical trials.
This trial tests a new pill, dabogratinib, for people with low grade cancer in the upper urinary tract (the tubes that carry urine from the kidneys to the bladder). It may help shrink or control the cancer without needing surgery to remove the kidney.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have low grade cancer in the upper urinary tract that was not fully removed (a marker lesion of at least 5 mm is left).
- You have not had BCG (a bladder treatment) in the past year, or bladder chemotherapy in the past 8 weeks.
- You have not had systemic chemotherapy in the past 3 months or immunotherapy in the past 6 months.
- Your kidney, liver, and blood counts are within certain limits (your doctor will check).
- You have not had high grade cancer or certain other types of bladder cancer before, and no prior FGFR inhibitor treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, nadofaragene firadenovec, which uses a harmless virus to deliver a signal that helps your immune system fight low-grade cancer in the upper part of the urinary tract (the kidney area). It's given directly into the kidney through a small tube, and may avoid more invasive surgery.
This trial tests a new pill, TYRA-300, for people with a certain type of early-stage bladder cancer that has a specific genetic change (FGFR3). The goal is to see if it can help by targeting the cancer cells and possibly avoiding more invasive treatments.
This trial tests a new treatment called UGN-104 for people with low-grade upper tract urothelial cancer (a type of cancer in the tube that carries urine from the kidney to the bladder). The treatment is given directly into the kidney area to kill cancer cells without surgery.
This trial is for people with upper tract urothelial cancer who have already had surgery and chemotherapy (cisplatin-based). It tests whether continuing with a drug called avelumab (an immunotherapy) can help prevent the cancer from coming back.
This trial tests whether combining the immunotherapy drug tislelizumab with the chemotherapy drug nab-paclitaxel before surgery can help treat high-risk upper tract urothelial cancer. The goal is to shrink the tumor and improve outcomes for patients who are planning to have their kidney and ureter removed.
This trial tests whether adding an immunotherapy drug (durvalumab) to chemotherapy before surgery can improve outcomes for people with high-grade upper tract urothelial cancer. It compares different treatment approaches based on whether a patient can receive cisplatin chemotherapy.
Hear when a new Low Grade Upper Tract Urothelial Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.